These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 17095528)

  • 1. Low-level liver enzyme elevations during HAART are not associated with liver fibrosis progression among HIV/HCV-coinfected patients.
    Vergara S; Macías J; Mira JA; García-García JA; Merchante N; del Valle J; Abdel-Kader L; Lozano F; Gómez-Mateos JM; Pineda JA
    J Antimicrob Chemother; 2007 Jan; 59(1):87-91. PubMed ID: 17095528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.
    Macías J; Mira JA; López-Cortés LF; Santos I; Girón-González JA; González-Serrano M; Merino D; Hernández-Quero J; Rivero A; Merchante N; Trastoy M; Carrillo-Gómez R; Arizcorreta-Yarza A; Gómez-Mateos J; Pineda JA
    Antivir Ther; 2006; 11(7):839-46. PubMed ID: 17302246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection.
    Mehta SH; Thomas DL; Torbenson M; Brinkley S; Mirel L; Chaisson RE; Moore RD; Sulkowski MS
    Hepatology; 2005 Jan; 41(1):123-31. PubMed ID: 15619237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus.
    Martinez-Sierra C; Arizcorreta A; Díaz F; Roldán R; Martín-Herrera L; Pérez-Guzmán E; Girón-González JA
    Clin Infect Dis; 2003 Feb; 36(4):491-8. PubMed ID: 12567308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver enzymes elevation after HAART in HIV-HCV co-infection.
    Servin-Abad L; Molina E; Baracco G; Arosemena L; Regev A; Jeffers L; Schiff E
    J Viral Hepat; 2005 Jul; 12(4):429-34. PubMed ID: 15985015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver biopsy findings for HIV-infected patients with chronic hepatitis C and persistently normal levels of alanine aminotransferase.
    Sánchez-Conde M; Berenguer J; Miralles P; Alvarez F; Carlos Lopez J; Cosin J; Pilar C; Ramirez M; Gutierrez I; Alvarez E
    Clin Infect Dis; 2006 Sep; 43(5):640-4. PubMed ID: 16886160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for fibrosis progression in HIV/HCV coinfected patients from a retrospective analysis of liver biopsies in 1985-2002.
    Schiavini M; Angeli E; Mainini A; Zerbi P; Duca PG; Gubertini G; Vago L; Fociani P; Giorgi R; Cargnel A
    HIV Med; 2006 Jul; 7(5):331-7. PubMed ID: 16945079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression of liver fibrosis in patients coinfected with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy.
    Pineda JA; Macías J
    J Antimicrob Chemother; 2005 Apr; 55(4):417-9. PubMed ID: 15731202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.
    Vispo E; Mena A; Maida I; Blanco F; Cordoba M; Labarga P; Rodriguez-Novoa S; Alvarez E; Jimenez-Nacher I; Soriano V
    J Antimicrob Chemother; 2010 Mar; 65(3):543-7. PubMed ID: 20032006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of HAART on liver histology of HIV/HCV coinfected patients.
    De Bona A; Sitia G; Uberti-Foppa C; Galli L; Ciuffreda D; Gallotta G; Paties C; Lazzarin A
    J Biol Regul Homeost Agents; 2003; 17(2):195-7. PubMed ID: 14518723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.
    Pineda JA; Santos J; Rivero A; Abdel-Kader L; Palacios R; Camacho A; Lozano F; Macías J;
    J Antimicrob Chemother; 2008 Apr; 61(4):925-32. PubMed ID: 18276600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Documented rapid course of hepatic fibrosis between two biopsies in patients coinfected by HIV and HCV despite high CD4 cell count.
    Bonnard P; Lescure FX; Amiel C; Guiard-Schmid JB; Callard P; Gharakhanian S; Pialoux G
    J Viral Hepat; 2007 Nov; 14(11):806-11. PubMed ID: 17927617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults.
    Sulkowski MS; Mehta SH; Torbenson MS; Higgins Y; Brinkley SC; de Oca RM; Moore RD; Afdhal NH; Thomas DL
    AIDS; 2007 Oct; 21(16):2209-16. PubMed ID: 18090048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin resistance is not associated with liver fibrosis progression in HIV/hepatitis C virus-coinfected patients.
    Merchante N; Macías J; Ramayo E; Vergara S; García-García JA; Mira JA; Corzo JE; Gómez-Mateos JM; Lozano F; Pineda JA
    J Viral Hepat; 2006 Jul; 13(7):449-56. PubMed ID: 16792538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients.
    Stone SF; Lee S; Keane NM; Price P; French MA
    J Infect Dis; 2002 Nov; 186(10):1498-502. PubMed ID: 12404169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV coinfection and antiretroviral therapy enhances liver steatosis in patients with hepatitis C, but only in those infected by HCV genotype other than 3.
    Borghi V; Puoti M; Mussini C; Bellelli S; Angeletti C; Sabbatini F; Prati F; Cossarizza A; Esposito R
    Antivir Ther; 2008; 13(8):1057-65. PubMed ID: 19195331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis.
    Gatti F; Nasta P; Loregian A; Puoti M; Matti A; Pagni S; de Requena DG; Prestini K; Parisi SG; Bonora S; Palù G; Carosi G
    J Antimicrob Chemother; 2009 Mar; 63(3):575-8. PubMed ID: 19151039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?
    Cicconi P; Cozzi-Lepri A; Phillips A; Puoti M; Antonucci G; Manconi PE; Tositti G; Colangeli V; Lichtner M; Monforte Ad;
    AIDS; 2007 Mar; 21(5):599-606. PubMed ID: 17314522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center.
    Testillano M; Fernandez JR; Suarez MJ; Gastaca M; Bustamante J; Pijoan JI; Montejo M; Valdivieso A; Ruiz P; Gonzalez J; Ortiz de Urbina J
    Transplant Proc; 2009 Apr; 41(3):1041-3. PubMed ID: 19376421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HAART attenuates liver fibrosis in patients with HIV/HCV co-infection: fact or fiction?
    Verma S
    J Antimicrob Chemother; 2006 Sep; 58(3):496-501. PubMed ID: 16854955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.